Top

Published in:

01-07-2020 | Prostate Cancer | Original Article

Association between acute histopathological changes of rectal walls and late radiation proctitis following radiotherapy for prostate cancer+

Authors: Franco Campostrini, MD, Andrea Remo, MD, Laura Astati, BS, Manuel Zorzi, MD, Giulia Capodaglio, ScD, Alberto Buffoli, MD, Gaia Moretti, M Ph, Barbara Della Monica, M Ph, Caterina Zanella, MD, Giuseppe Verlato, PhD

Published in: Strahlentherapie und Onkologie | Issue 7/2020

Abstract

Purpose

The impact of acute histopathological changes (HC) of the rectum on development of late clinical proctitis (LCP) after external radiotherapy (RT) for prostate cancer is poorly explored and was the primary end point of this prospective study.

Methods

In 70 patients, 15 HC of early rectal biopsies after RT were identified, whereby RT was conventional 2D RT in 41 cases and conformational 3D RT in 29. Associations of HC in anterior and posterior rectal walls (ARW, PRW) with LCP, acute endoscopic (AEP) and acute clinical proctitis (ACP) were statistically evaluated considering as explicative variables the patient general characteristics and the HC.

Results

The mean patients’ follow-up was 123.5 months (24–209). The median prostatic dose was 72 Gy (2 Gy/fraction). For the 41 and 29 patients the ARW and PRW doses were 64 and 49 Gy vs. 63 and 50 Gy, respectively. The incidence of LCP ≥ grade 2 at 10 years was 12.9%. The univariate (p = 0.02) and Kaplan–Meyer methods (p = 0.007) showed that the gland (or crypts) loss in the ARW was significantly associated with LCP. AEP and ACP occurred in 14.3 and 55.7% of cases. At multivariate level AEP significantly correlated with hemorrhoids (p = 0.014) and neutrophilia in ARW (p = 0.042).

Conclusions

Early after RT, substantial gland loss in ARW is predictive of LCP. To reduce this complication with conventional fractionation, we suggest keeping the mean dose to ARW ≤48–52 Gy.

Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V et al (2014) Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88:1074–1084CrossRef

Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17:464–467CrossRef

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060CrossRef

Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G et al (2017) Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial. J Clin Oncol 35:1891–1897CrossRef

Onjukka E, Fiorino C, Cicchetti A, Palorini F, Improta I, Gagliardi G et al (2019) Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT. Acta Oncol 12:1–8

Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ et al (2018) Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol 36:2943–2949CrossRef

Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35:1884–1890CrossRef

Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A (2013) A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 13:49CrossRef

Musunuru HB, Quon H, Davidson M, Cheung P, Zhang L, D’Alimonte L et al (2016) Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials. Radiother Oncol 118:112–117CrossRef

10.

Paleny R, Bremer M, Walacides D, Mainwaring S, Weber K, Henkenberens C (2019) Comparison of relative and absolute rectal dose-volume parameters and clinical correlation with acute and late radiation proctitis in prostate cancer patients. Strahlenther Onkol 195:103–112CrossRef

11.

Michalsky JF, Gay H, Jackson A, Tucker SL, Deasy JO (2010) Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):S123–S129CrossRef

12.

Grodsky MB, Sidani SM (2015) Radiation proctopathy. Clin Colon Rectal Surg 28:103–111CrossRef

13.

Campostrini F, Musola R, Marchiaro G, Lonardi F, Verlato G (2013) Role of early proctoscopy in predicting late symptomatic proctitis after external radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 85:1031–1037CrossRef

14.

Reddy EK, Giri S, Mansfield CM (1984) External radiation therapy of localized prostatic cancer. J Natl Med Assoc 76:61–66PubMedPubMedCentral

15.

Dewit L, van der Schueren E (1984) Radiation treatment planning for the localized prostatic carcinoma: methods and rationale. Strahlentherapie 8:474–484

16.

Campostrini F, Garusi G, Donati E (1995) A practical technique for conformal simulation in radiation therapy of pelvic tumors. Int J Radiat Oncol Biol Phys 15:355–365CrossRef

17.

Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL et al (1996) Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34:555–564CrossRef

18.

Wachter S, Gerstner N, Goldner G, Pötzi R, Wambersie A, Pötter R (2000) Endoscopic scoring of late rectal mucosa damage after conformal radiotherapy for prostate carcinoma. Radiother Oncol 54:11–19CrossRef

19.

Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG et al (1998) Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 115:525–532CrossRef

20.

Hovdenak N, Fajardo LF, Hauer Jensen M (2000) Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 48:1111–1117CrossRef

21.

Leupin N, Curschmann J, Kranzbühler H, Maurer CA, Laissue JA, Mazzucchelli L (2002) Acute radiation colitis in patients treated with short-term preoperative radiotherapy for rectal cancer. Am J Surg Pathol 26:498–504CrossRef

22.

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346CrossRef

23.

Crespi M, Delvaux M, Schaprio M, Venables C, Zwiebel F (1996) Working Party Report by the Committee for Minimal Standards of Terminology and Documentation in Digestive Endoscopy of the European Society of Gastrointestinal Endoscopy. Minimal standard terminology for a computerized endoscopic database. Ad hoc Task Force of the Committee. Am J Gastroenterol 91:191–216PubMed

24.

Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S et al (2009) Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol 93:226–233CrossRef

25.

Gelfand MD, Tepper M, Katz LA, Binder HJ, Yesner R, Floch MH (1968) Acute irradiation proctitis in man. Development of eosinophilic crypt abscesses. Gastroenterology 1:401–411CrossRef

26.

Tepper M, Vidone RA, Hayes MA, Lindenmuth WW, Kligerman MM (1968) Preoperative irradiation in rectal cancer: initial comparison of clinical tolerance, surgical and pathologic findings. AJR Am J Roentgenol 102:587–595CrossRef

27.

Weisbrot IM, Liber AF, Gordon BS (1975) The effects of therapeutic radiation on colonic mucosa. Cancer 36:931–940CrossRef

28.

Haboubi NY, Schofield PF, Rowland PL (1988) The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol 83:1140–1144PubMed

29.

Sedgwick DM, Howard GCW, Ferguson A (1994) Pathogenesis of acute radiation injury to the rectum. A prospective study in patients. Int J Colorect Dis 9:23–30CrossRef

30.

Karamanolis G, Delladetsima I, Kouloulias V, Papaxoinis K, Panayiotides I, Haldeopoulos D et al (2013) Increased expression of VEGF and CD31 in postradiation rectal tissue: implications for radiation proctitis. Mediators Inflamm. https://doi.org/10.1155/2013/515048CrossRefPubMedPubMedCentral

31.

Richter KK, Wang J, Fagerhol MK, Hauer-Jensen M (2001) Radiation-induced granulocyte transmigration predicts development of delayed structural changes in rat intestine. Radiother Oncol 59:81–85CrossRef

32.

Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H et al (2010) Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 76:747–754CrossRef

33.

Smit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath JJ, van der Werf-Messing BH (1990) Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18:23–29CrossRef

34.

Zilli T, Jorcano S, Escudé L, Linero D, Rouzaud M, Dubouloz A et al (2011) Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement. Toxicity and outcome from a dose escalation pilot study. Int J Radiat Oncol Biol Phys 81:382–389CrossRef

35.

Ren W, Sun C, Lu N, Xu Y, Han F, Liu YP et al (2016) Dosimetric comparison of intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy in patients with prostate cancer: a meta-analysis. J Appl Clin Med Phys 17:254–262CrossRef

36.

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‑year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385–395CrossRef

37.

Kittel JA, Reddy CA, Smith KL, Stephans KL, Tendulkar RD, Ulchaker J et al (2015) Long-term efficacy and toxicity of low-dose-rate ¹²⁵I prostate Brachytherapy as Monotherapy in low-, intermediate-, and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 92:884–893CrossRef

38.

Mendez LC, Morton GC (2018) High dose-rate brachytherapy in the treatment of prostate cancer. Transl Androl Urol 2018(7):357–370CrossRef

39.

Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H et al (2017) ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 8:286–295CrossRef

Title: Association between acute histopathological changes of rectal walls and late radiation proctitis following radiotherapy for prostate cancer+
Authors: Franco Campostrini, MD
Andrea Remo, MD
Laura Astati, BS
Manuel Zorzi, MD
Giulia Capodaglio, ScD
Alberto Buffoli, MD
Gaia Moretti, M Ph
Barbara Della Monica, M Ph
Caterina Zanella, MD
Giuseppe Verlato, PhD
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Proctitis
Prostate Cancer
Radiotherapy
Published in: Strahlentherapie und Onkologie / Issue 7/2020
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-020-01590-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Association between acute histopathological changes of rectal walls and late radiation proctitis following radiotherapy for prostate cancer+

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2020

PSMA-positive nodal recurrence in prostate cancer

Adaptive radiotherapy and the dosimetric impact of inter- and intrafractional motion on the planning target volume for prostate cancer patients

Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer

Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer

Intensitätsmodulierte fraktionierte Radiotherapie vs. körperstereotaktische Radiotherapie des Prostatakarzinoms (PACE-B) – akute Toxizität aus einer internationalen, randomisierten Phase-III-Nichtunterlegenheitsstudie

Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer